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Abstract 
 
Background - attempts to reduce the burden of vascular disease in advanced 
chronic kidney disease (CKD) by control of lipids have not been as successful 
as predicted. 
Aim - to determine the extent to which the effectiveness of statins varies by 
kidney class. 
Design - meta-analysis  
Methods – we selected randomised trials of statin versus placebo that gave 
outcomes for CKD3 (eGFR 30-59ml/min), CKD4 (eGFR 15-29ml/min), CKD5 
(eGFR <15ml/min)/5D(dialysis) and transplant patients separately. Data 
sources were the Cholesterol Triallists’ Treatment Collaboration and 
previously published meta-analyses. Main outcome measures were major 
cardiovascular events (MACE), cardiovascular death and all cause mortality. 
Results – 13 studies provided 19386 participants with CKD3, 2565 with CKD4, 
7051 with CKD5/5D and 2102 with a functioning renal transplant. Statins 
reduced MACE (pooled HR 0.72, 95% CI 0.67 to 0.78) and all-cause mortality 
(0.82, 0.73 to 0.91) in CKD3; probably reduced MACE (0.78, 0.62 to 0.99) in 
CKD4; and probably reduced cardiovascular death (0.62, 0.40 to 0.96) in renal 
transplants.  There were no cardiovascular or all cause mortality data in CKD4;  
there was no convincing evidence of benefit for any outcome in CKD5/5D; and 
no significant reduction in MACE or all cause mortality in patients with a 
functioning transplant.   
Conclusions - statins are indicated in CKD3, probably indicated in CKD4, not 
indicated in CKD5/5D and probably indicated in patients with a functioning 
transplant.  Too few patients with CKD4 and renal transplants have been 
included in lipid lowering trials for confident conclusions to be drawn. 
Word count 244 
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Strengths and Limitations of this Study 
 Strength - we analysed patients with CKD3, CKD4, CKD5/5D and renal 
transplant separately and  
 Strength – we were able to include 19,386 patients with CKD3. 
 Strength - we included all relevant studies published by 11/5/16. 
 Limitation – our meta-analysis includes RCTs of patients with CKD 
together with post hoc CKD substudies of general population surveys. 
 Limitation - definitions of MACE and cardiovascular death often differed 
between trials. 
What is already known on this subject 
 
 People with chronic kidney disease (CKD) carry a high risk of vascular 
disease and are much more likely to die from vascular causes than those 
who do not have CKD.  
 Attempts to reduce the burden of vascular disease in advanced CKD by 
control of lipids have not been as successful as predicted. 
 
What this study adds 
 
 Statins are indicated in CKD3, probably indicated in CKD4, not 
indicated in CKD5/5D and probably indicated in patients with a 
functioning transplant.   
 Too few patients with CKD4 and transplants have been included in lipid 
lowering trials for confident conclusions to be drawn. 
 
Key Words 
Major cardiovascular events.  Cardiovascular mortality.  All cause mortality.  
Statins.  Chronic kidney disease.  Meta-analysis.  
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Introduction 
 
People with chronic kidney disease (CKD) carry a high risk of vascular disease 
and are much more likely to die from vascular causes than those who do not 
have CKD1.   The risk of vascular death increases with the severity of CKD and 
may be between 8 and 10 times greater than that of the general population 
by the time a patient starts dialysis2.  It is disappointing therefore that 
attempts to reduce the burden of vascular disease in advanced CKD by control 
of lipids have not been as successful as predicted3-6, contradicting the widely 
held view that patients at higher risk of disease generally benefit more from 
treatment.   
 
Eight meta-analyses of lipid lowering in renal disease have been published.   
The most recent and largest of these, the Cholesterol Triallists Treatment 
Collaboration, chose not to present data for patients with CKD4 or with renal 
transplants separately7.  Palmer et al considered all patients from those 
microalbuminuria to CKD5 as one group then compared outcomes with 
patients on dialysis and patients with transplant8.  Both Upadhyay9 and Su910 
pooled outcomes for all patients from microalbuminuria to transplant.  Hou et 
al combined CKD2 and CKD3 before comparing outcomes with a combined 
group of CKD4 and CKD5/5D11.  Green and colleagues limited their analysis to 
dialysis patients only12 while Major et al limited theirs to patients with CKD3 
and no prior coronary heart disease (CHD)13.  The meta-analysis by Yan and 
colleagues was primarily a comparison of more versus less statin14.  With one 
exception8 the authors of the meta-analyses comparing statins with placebo 
felt their findings supported the widespread use of statins in patients with 
CKD.  Yan et al concluded that the benefits of high intensity statin therapy 
were unclear14. 
We chose not to replicate these studies for two reasons:  first, we did not wish 
to include patients with microalbuminuria and CKD2 as this would have meant 
assessing all trials of statins in older adults which was not our primary 
objective; and second, we felt that pooling patients with different severity of 
CKD would assume that all patients with CKD behave similarly irrespective of 
stage.  We do not believe that this is the case.  Indeed it would appear that 
statins are more effective in CKD3 than in patients on dialysis15.  We suspect 
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this is a consequence of a change in the nature of the vascular disease in 
kidney patients from primarily atherosclerotic to predominantly calcific 
pathology with myocardial fibrosis an important contributory factor1.  If true 
this might be a reason why statins lose their benefit as renal failure 
progresses.  
 
Against this background the aim of our meta-analysis was to quantify the 
benefits of statin therapy at different stages of CKD and to determine the 
point at which statins become less effective by examining, where possible, 
patients with CKD3 (eGFR 30-59ml/min), CKD4 (eGFR 15-29ml/min), CKD5 
(eGFR <15ml/min)/5D (patients on dialysis) and those with renal transplant 
separately.  
 
Methods 
 
We selected studies by checking the reference lists of previous systematic 
reviews in order to avoid duplicating the work of others.  Sources of studies 
about the effect of statins in patients with CKD were the Cholesterol 
Treatment Triallists Collaboration7, the meta-analyses by Palmer8, Upadhyay9, 
Su10, Hou11, Green12, Major13 and Yan14, and the Cochrane Review by Taylor et 
al16. 
From these reports we included randomised trials of statin versus placebo 
that gave outcomes for CKD3, CKD4, CKD5, dialysis (CKD5D) or transplant 
patients separately in their main results papers, in CKD substudies or in pooled 
analyses. Four trials were conducted exclusively in subjects with CKD3-6, eight 
were CKD substudies of primary or secondary prevention trials17-24 and one 
was a pooled analysis of WOSCOPS, CARE and LIPID25. We excluded studies 
with fewer than 300 patients, trials of more versus less statin but no placebo 
group26-28, trials of less than one year’s duration29 and an open label extension 
to ALERT that increased average follow up from 5.1 to 6.7 years for patients 
randomized to fluvastatin30 .  
We independently extracted data for the following three outcomes: major 
cardiovascular events (MACE), cardiovascular death and all cause mortality 
(ACM); and for the following five categories of CKD: CKD3, CKD4, CKD5, 
dialysis (CKD5D) and renal transplant. The definitions of MACE and 
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cardiovascular death varied, as shown in Appendix 1.  
We obtained hazard ratios and confidence intervals from each paper and 
derived variances of the log hazard ratios from the reported confidence 
intervals. For the LIPS substudy23, log hazard ratio and variance were derived 
from the numbers at risk and numbers of events per year given in the paper, 
using the method suggested by Parmar et al31.  We weighted results by the 
inverse of the variance of the log hazard ratio and derived pooled effects 
within each CKD group by fitting a meta regression model predicting log 
hazard ratio from CKD class.   We used mixed effect models to account for 
heterogeneity of the studies. To quantify residual heterogeneity, I2 and τ2 were 
calculated for each regression model.  In addition, we performed a sensitivity 
analysis incorporating an indicator for study type, namely study in CKD 
patients only vs. CKD substudy, into the model.  All statistical analysis was 
carried out using R version 3.2.432 with packages MAd33 and metafor34 
Patient involvement 
No patients were involved in setting the research question or the outcome 
measures, nor were patients involved in the design and implementation of the 
study.  There are no plans to involve patients in disseminating the results. 
 
Results 
                                                             
Table 1 shows the characteristics of the 13 studies in our meta-analysis.  
17263 participants in eight primary or secondary prevention trials and one 
pooled analysis had CKD3.  One trial had a mixed population of both dialysis 
and non-dialysis patients including 2111 with CKD3, 2565 with CKD4, 1221 
with CKD5 and 3023 with CKD5D.  Two trials were conducted exclusively in 
patients on dialysis contributing 4028 to a total of 8272 CKD5/5D patients for 
the meta-analysis.   One trial with 2102 participants was undertaken in 
patients with a functioning renal transplant.  Study duration varied from 1.9 to 
5.5 years.  
 
Table 1 about here 
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Baseline estimated GFR was as reported in the original papers.  All included 
trials were placebo controlled.  Six different statins were assessed: pravastatin 
in 3 trials, atorvastatin, rosuvastatin, simvastatin and fluvastatin in 2 trials 
each, lovastatin in one trial.  One trial tested a combination of simvastatin and 
ezetimibe.  The statin dose, absolute and percentage LDL reduction and 
achieved LDL in each trial are as shown.  There is a suggestion here that 
absolute LDL reduction was less in the trials of patients with more advanced 
renal failure.  All 13 studies reported MACE, 4 reported cardiovascular 
mortality while 9 reported all cause mortality.  The total number of events 
available for meta-analysis were 5406, 1183 and 3518 for MACE, 
cardiovascular death and all cause mortality respectively.  
 
The number of events with hazard ratios and confidence intervals for each 
end point are given by trial in Table 2 and by CKD class in Figure 1.  For MACE, 
we found a significant protective treatment effect for CKD3 (HR 0.72, 95%CI 
0.67-0.78, p<0.001) and CKD4 (HR 0.78, 95%CI 0.61-0.99, p=0.041), but not for 
CKD5/5D (HR 0.92, 95%CI 0.84-1.02, p=0.099) or transplant patients (HR 0.83, 
95%CI 0.64-1.08, p=0.161). The treatment effect in CKD3 was significantly 
stronger than for CKD5/5D (p<0.001), other pairwise comparisons were not 
significant.  Residual heterogeneity of the model was low (I2=8.06%, p=0.235). 
In the sensitivity analysis for MACE, study type was not significant (p=0.723). 
 
For all-cause mortality, we found again that the treatment effect was 
strongest in CKD3 (HR 0.82, 95%CI 0.73 to 0.91, p=0.001) with no significant 
benefit in CKD5/5D (HR 0.95, 95%CI 0.87 to 1.04, p=0.262) or transplant 
patients (HR 1.02, 95%CI 0.81 to 1.29, p=0.870). The treatment effect was 
stronger in CKD3 than in CKD5/5D (p=0.040), otherwise pairwise comparisons 
were not significant.  There were no all cause mortality data for CKD4.  
Residual heterogeneity of the model was low (I2=0.00%, p=0.291).   
 
For cardiovascular mortality, we noted a significant treatment effect in 
transplant patients (HR 0.62, 95%CI 0.40 to 0.96, p=0.031) but no significant 
benefit for CKD3 (HR 0.75, 95%CI 0.52 to 1.09, p=0.130) or CKD5/5D (HR 0.92, 
95%CI 0.75 to 1.12, p=0.409). Pairwise comparisons were not significant.  
There were no cardiovascular mortality data for CKD4.  There was residual 
heterogeneity (I2 52.64%), but homogeneity was not rejected (p=0.146). 
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Table 2 and Figure 1 about here 
 
There were 9674 subjects with CKD3 in five primary prevention trials and 9712 
subjects with CKD3 in five trials that included a significant proportion of 
subjects with prior CHD (Table 1).  Splitting CKD3 into those with and without 
prior CHD and repeating the analyses for MACE and ACM (none of the primary 
prevention trials reported cardiovascular mortality), we found that the 
benefits of statins were not simply confined to CKD3 participants with CHD. 
Hazard ratios for MACE were 0.75 (95% CI 0.70 to 0.81, p<0.001) for those 
with and 0.60 (95%CI 0.50 to 0.72, p<0.001) for those without prior CHD.  The 
treatment effect in CKD3 without prior CHD was significantly stronger than for 
CKD3 with prior CHD (p=0.023).  Residual heterogeneity of the model was low 
(I2=0.00%, p=0.533). 
 
Corresponding hazard ratios for all cause mortality in CKD3 were 0.86 (95%CI 
0.76 to 0.97, p=0.013) for those with and 0.62 (95%CI 0.46 to 0.822, p=0.001) 
for those without prior CHD.  Again, there was a significant difference in the 
treatment effects between CKD3 with and without prior CHD, favouring those 
without CHD (p=0.036).  Residual heterogeneity of the model was low 
(I2=0.03%, p=0.712).  There was no difference in treatment effects for MACE 
when we split CKD 5/5D into trials that included or did not include patients 
with prior CHD (analysis not possible for ACM or cardiovascular mortality), 
though we recognise this could also be due to low numbers of events in 
subgroups. 
 
 
Discussion  
 
The authors of SHARP, the largest of the lipid lowering trials in patients with 
CKD, interpreted the results of that trial as supporting the widespread use of 
statins in both dialysis and non-dialysis patients6.  That view has since been 
challenged by the consistent failure of lipid lowering studies to benefit dialysis 
patients, leading KDIGO in 2014 to recommend treatment with statin or 
statin/ezetimibe combination in adults aged >= 50 years with eGFR <60ml/min 
but not treated with renal replacement therapy or renal transplant15.    
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There is an assumption here that all predialysis patients will benefit and it is 
possibly for this reason that none of the recent guidelines distinguish between 
CKD3, CKD4 and CKD5.  The Joint British Societies 3 Guideline suggests that 
lipid lowering therapy with statins be considered in all adults with stages 3-5 
CKD35, while NICE advise atorvastatin 20 mg daily for the primary or secondary 
prevention of CVD for all people with CKD (which they define as eGFR 
<60ml/min and/or urine ACR >3mg/mmol)36.  Five of the eight CKD meta-
analyses came to essentially the same conclusion, namely that statins be 
considered for cardiovascular disease prevention in most patients with CKD9-
13.  The CTTC observed a trend towards smaller reduction in major vascular 
events as eGFR declined but did not advise against treating patients with 
advanced renal failure, concluding instead that statin based regimens should 
be chosen to maximise the absolute reduction in LDL cholesterol to achieve 
the largest treatment benefit7. 
 
Pooling patients with CKD3, 4 and 5 seems illogical to us for two reasons: first, 
CKD3 occurs in up to one third of UK adults over 75 years of age and is around 
20x more common than CKD4 and 537; and second, pooling takes no account 
of the change in pathophysiology of the vascular disease from atherosclerotic 
to calcific arteriopathy and myocardial fibrosis as renal failure progresses1.   
The other meta-analyses7-14 did not address this question directly and it was 
for this reason that we undertook our own. 
 
The main findings of our meta-analysis were as follows. We found a 
convincing benefit of statins for MACE and all cause mortality in CKD3 
especially in patients without prior CHD but also in those with prior CHD.  
Reduction of cardiovascular mortality in CKD3 is not significant, but the 
estimated HR is of similar magnitude. In CKD4, statins reduce MACE 
significantly but for ACM and cardiovascular mortality there are no data.   In 
CKD5/5D, estimated treatment effects are small and not significant for any of 
the endpoints.   In transplant patients the results do not suggest a treatment 
effect on ACM or MACE.   For cardiovascular mortality, there appears to be a 
protective effect which just achieves statistical significance.  We are aware 
that an open label extension to ALERT has suggested a likely benefit for MACE 
but since both groups received statins in the extension period we did not feel 
that those results could be incorporated in the meta-analysis30 .  
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There are several possible explanations why statins become less effective at 
reducing vascular events as renal function declines.   First, the changes in 
pathophysiology described above may lead to death from heart failure and 
arrhythmia rather than myocardial infarction1. We would not expect lipid-
lowering therapy to benefit either of these conditions.  Second, dialysis 
patients have additional uremia-related risk factors that include anaemia, 
hyperphosphatemia, oxidative stress, inflammation, and accumulation of the 
endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine, 
which results in reduced nitric oxide synthesis and may significantly contribute 
to CVD1.  Again, none of these factors are likely to be improved by lipid 
lowering therapy.  Third, it is possible that failure to demonstrate benefit with 
statins in patients with more severe kidney disease reflects lower baseline LDL 
cholesterol and smaller absolute reductions in LDL cholesterol as eGFR 
declines7.  However, the CTTC adjusted for these possibilities by reporting 
event rates per mmol of LDL reduction and showed that the relative reduction 
in major vascular events observed with statin-based treatment does indeed 
become smaller as renal failure progresses7 
 
Our meta-analysis did not directly address the question whether benefit in 
CKD3 reflected statin responsive atherosclerotic disease and that failure to 
benefit in CKD5/5D was a consequence of calcific arteriopathy/myocardial 
fibrosis, though this may be inferred from a comparison of outcomes in 
WOSCOPS38 and SHARP6.  WOSCOPS was a primary prevention trial of middle 
aged men with essentially normal renal function whereas SHARP was a trial of 
men and women, 27% of whom had CKD3 and 73% CKD4+CKD5/5D.  Average 
follow up in both trials was 4.9 years.  All cause mortality in SHARP 
participants randomized to placebo was 6x that of the WOSCOPS placebo 
group, yet the proportion of participants who died a CHD death in the placebo 
groups of SHARP and WOSCOPS was identical (Figure 2).   CHD deaths were 
responsible for only 7.9% of SHARP deaths but for 46.3% of WOSCOPS deaths.   
If statins were only able to reduce the incidence of CHD deaths in both trials 
then it is perhaps unsurprising that statins appeared less effective in SHARP 
than in WOSCOPS. 
 
Figure 2 about here 
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We acknowledge limitations.  In our comparison of statin trials it was not 
always possible to compare like with like as definitions of MACE and 
cardiovascular death differed.   Some of these differences were minor and 
some not (Appendix 1).   AURORA included fatal stroke in their cardiovascular 
deaths5 whereas 4D did not4.  Cardiovascular deaths in ALERT were cardiac 
deaths only3.  In each of these examples the choice of endpoint may have 
inadvertently influenced the result of the trial in question:  respectively more 
fatal strokes and non-cardiac vascular deaths occurred in 4D and ALERT 
patients who were randomised to statin therapy. There is, moreover, no 
agreed method for determining the precise cause of vascular death in patients 
with advanced CKD, an issue that has recently been addressed, though not 
completely resolved, by the CTTC meta-analysis7.   We also recognise that we 
did not attempt to analyse outcomes other than MACE, vascular death and all 
cause mortality.  Others have done so and have found no increase in risk of 
adverse events16 with the possible exception of type 2 diabetes39. 
 
We accept that our analysis sheds no light on the question whether statins 
started in CKD3 should be stopped if and when a patient reaches stage 5/5D. 
The trials were of patients starting statins in different stages of CKD and didn’t 
include patients already on statins.  We further acknowledge that we relied on 
local expertise, previously published meta-analyses and systematic reviews 
rather than duplicate the work of others by conducting a formal literature 
search. As a direct consequence of this approach, however, we were able to 
incorporate data from PROSPER that were not included in several other meta-
analyses8-11,13, allowing us to analyse results from no fewer than 19386 
subjects with CKD3.  We are confident that this strategy has yielded all 
relevant studies up to and including those published by 11th May 2016 and 
that risk of bias in included trials was low7. 
 
Based on our meta-analysis and on our interpretation of the literature we 
believe that statins are indicated in CKD3, probably indicated in CKD4, not 
indicated in CKD5/5D and probably indicated in patients with a functioning 
transplant.  We do not feel the available evidence currently supports the more 
widespread use of statins in CKD that has been recommended by some 
authorities9,11,13,35,36 simply because the trials and meta-analyses on which 
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their recommendations are based have not yet included large enough 
numbers of patients with CKD4 and functioning renal transplants for confident 
conclusions to be drawn. 
 
Word count 2852 (excl abstract) 
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Appendix 1 - Vascular end points  
 
MACE 
 
4S - coronary deaths, definite or probable hospital verified nonfatal acute MI, 
resuscitated cardiac arrest, and definite silent MI verified by using 
electrocardiogram.                                                                                                  
AFCAPS/TEXCAPS - unstable angina, fatal or nonfatal MI, and sudden cardiac 
death. 
CARDS – acute CHD death, nonfatal MI including silent MI, hospitalized 
unstable angina, resuscitated cardiac arrest, coronary revascularization or 
stroke.                                                                               
HPS - nonfatal MI, death from coronary disease, strokes of any type, and 
coronary or non-coronary revascularization.                                                                                                 
JUPITER - nonfatal MI, nonfatal stroke, hospital stay for unstable angina, 
arterial revascularization, or confirmed cardiovascular death.                                                         
MEGA - fatal and nonfatal MI, angina pectoris, cardiac/sudden death, and 
coronary revascularization.                                                                                                                                          
LIPS - cardiac death (all deaths except those unequivocally related to a 
noncardiac cause), nonfatal MI and all reinterventions (surgical or 
percutaneous) not caused by coronary restenosis occurring after a first 
successful PCI.                                                                                                           
PPP - death from cardiovascular causes, non fatal MI, coronary 
revascularization or stroke                                                                                                                            
PROSPER - definite or suspected death from coronary heart disease, non-fatal 
MI, and fatal or non-fatal stroke.                                                                                                                   
SHARP - first non fatal MI or coronary death, non haemorrhagic stroke or any 
revascularisation procedure                                                                                                                         
4D - death from cardiovascular causes, non fatal MI or non fatal stroke.                                                                                                                             
AURORA - death from cardiovascular causes, non fatal MI or non fatal stroke.                                                                                                                             
ALERT - cardiac deaths, non fatal MI or coronary intervention procedures  
 
Cardiovascular deaths  
PROSPER – cardiac and other vascular deaths including fatal stroke                  
AURORA - cardiac and other vascular deaths including fatal stroke 
4D - cardiac and other vascular deaths excluding fatal stroke  
ALERT - cardiac deaths only.   
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Table 1 Baseline Characteristics of Included Studies 
 
 
 
 
Study CKD 
stage 
Definition of CKD Number 
of 
patients 
Prior 
CHD 
Active treatment Baseline 
LDL 
(mmol/l) 
LDL 
reduction 
(%) 
LDL 
reduction 
(mmol/l) 
 LDL 
achieved 
(mmol/l) 
Duration 
(years) 
MACE CV 
mortality 
All cause 
mortality 
 
AFCAPS CKD 3 eGFR <60ml/min (may include 
some patients with CKD4) 
304 No Lovastatin 20mg 3.9 27        1.05 2.85 5.2 Yes No No 
CARDS CKD 3 eGFR 30-60 ml/min                      
  (1 patient had CKD4) 
970 No Atorvastatin 10mg 3.1 41         1.27 1.83 3.9 Yes No Yes 
JUPITER CKD 3 eGFR 30-60ml/min                                     
(14 patients had eGFR <30 
ml/min) 
3267 No Rosuvastatin 10mg 2.8 52 
 
1.46 1.34 1.9 Yes No Yes 
MEGA CKD 3 eGFR 30-60ml/min 2978 No Pravastatin 40mg 4.0 19 0.76 3.24 5.3 Yes No Yes 
SHARP CKD 3 eGFR 30-59ml/min 2155 No Simvastatin 20mg 
and ezetimibe 10mg 
2.91 34 0.99 1.91 4.0 Yes No No 
4S CKD 3 eGFR 30-59ml/min 505 100% Simvastatin 40mg 4.92 28 
 
       1.37 3.53 5.5 Yes No Yes 
HPS CKD 3 Serum creatinine 11-200umol/l in 
women and 130-200umol/l in 
men 
1329 65% Simvastatin 40mg 3.43 29 
 
0.99 2.41 4.8 Yes No No 
LIPS CKD 3 Creatinine clearance <55.9ml/min 
with baseline serum creatinine 
<159umol/l 
310 100% Fluvastatin 40mg 3.4 24 
 
        0.82 2.58 3.8 Yes No No 
PROSPER CKD 3 eGFR 30-60ml/min 3077 44% Pravastatin 40mg 3.8 34 
 
1.29 2.51 3.2 Yes Yes Yes 
PPP CKD 3 eGFR 30-60ml/min 4491 74% Pravastatin 40mg 3.9 32 
 
        1.25 2.65 5.0 Yes No Yes 
SHARP CKD 4 eGFR 15-29ml/min 2565 No Simvastatin 20mg 
and ezetimibe 10mg 
2.9 36 
 
        1.04 1.86 4.0 Yes No No 
SHARP CKD 5 eGFR <15ml/min  
but not on dialysis 
1221 No Simvastatin 20mg 
and ezetimibe 10mg 
2.9 25 
 
0.73 2.17 4.0 Yes No No 
SHARP CKD 5D Dialysis 3023 No Simvastatin 20mg 
and ezetimibe 10mg 
2.6 23 
 
        0.60 2.00 4.0 Yes No No 
4D CKD 5D Dialysis 1255 29% Atorvastatin 20mg 3.1 42 1.3 1.8 4.0 Yes Yes Yes 
AURORA CKD 5D Dialysis 2773 40% Rosuvastatin 10mg 2.6 43         1.12 1.48 3.2 Yes Yes Yes 
ALERT TX Transplant 2102 10% Fluvastatin 40mg 4.1 32 1.31 2.79 5.1. Yes Yes Yes 
  1SHARP main results paper implies that baseline LDL was 2.9mmol/l for all non-dialysis patients.    2Data for all 4S patients with eGFR 
<75ml/min as LDL levels for those with eGFR 30-59ml/min not given separately. 3Data for all HPS trial participants as LDL levels in renal 
subgroup not given separately. 
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Table 2 Cardiovascular outcomes and all cause mortality by CKD class 
 
Study CKD stage Statin events 
(%) 
Placebo events  
(%) 
Estimated Hazard 
Ratio (95% CI) 
Major Atherosclerotic Cardiac Event (MACE) 
AFCAPS CKD 3 8/145 (5.5) 21/159 (13.2) 0.39 (0.16, 0.93) 
CARDS CKD 3 25/482 (5.2) 42/488 (8.6) 0.57 (0.35, 0.94) 
JUPITER CKD 3 40/1638 (2.4) 71/1629 (4.4) 0.56 (0.38, 0.82) 
MEGA CKD 3 33/1471 (2.2) 71/1507 (4.7) 0.45 (0.30, 0.69) 
SHARP CKD 3 87/1100 (7.9) 110/1055 (10.4) 0.75 (0.57, 1.00) 
4S CKD 3 53/245 (21.6) 77/260 (29.6) 
0.73 (0.54, 0.99) 
HPS CKD 3 182/646 (28.1) 268/683 (39.2) 
0.72 (0.62, 0.84) 
LIPS CKD 3 23/150 (15.3) 47/160 (29.4) 
0.51 (0.31, 0.82) 
PROSPER CKD 3 220/1548 (14.2) 287/1529 (18.6) 
0.74 (0.62, 0.88) 
PPP CKD 3 573/2217 (25.8) 730/2274 (32.1) 
0.79 (0.71, 0.88) 
SHARP CKD 4 127/1246 (10.2) 168/1319 (12.7) 0.78 (0.62, 0.98) 
SHARP CKD 5 67/614 (10.9) 81/607 (13.3) 0.82 (0.59, 1.13) 
SHARP CKD 5D 230/1533 (15.0) 246/1490 (16.5) 
0.90 (0.75, 1.08) 
4D CKD 5D 226/619 (36.5) 243/636 (38.2) 
0.92 (0.77, 1.10) 
AURORA CKD 5D 396/1389 (28.5) 408/1384 (29.5) 
0.96 (0.84, 1.11) 
ALERT TX 112/1050 (10.7) 134/1052 (12.7) 
0.83 (0.64, 1.06) 
Cardiovascular mortality 
PROSPER CKD 3 76/1548 (4.9) 99/1529 (6.5) 0.75 (0.58, 1.01) 
4D CKD 5D 121/619 (19.5) 149/636 (23.4) 0.81 (0.64, 1.03) 
AURORA CKD 5D 324/1389 (23.3) 324/1384 (23.4) 1.00 (0.85, 1.16) 
ALERT TX 36/1050 (3.4) 54/1052 (5.1) 0.62 (0.40, 0.96) 
All cause mortality 
CARDS CKD 3 27/482 (5.6) 30/488 (6.2) 0.86 (0.51, 1.45) 
JUPITER CKD 3 34/1638 (2.1) 61/1629 (3.7) 0.56 (0.37, 0.85) 
MEGA CKD 3 16/1471 (1.1) 34/1507 (2.3) 0.49 (0.27, 0.89) 
4S CKD 3 37/245 (15.1) 40/260 (15.4) 0.99 (0.64, 1.55) 
PPP CKD 3 322/2217 (14.5) 383/2274 (16.8) 0.86 (0.74, 1.00) 
PROSPER CKD 3 156/1548 (10.1) 184/1529 (12.0) 0.83 (0.67, 1.03) 
4D CKD 5D 297/619 (43.1) 320/636 (50.3) 0.93 (0.79, 1.08) 
AURORA CKD 5D 636/1389 (45.7) 660/1384 (47.7) 0.96 (0.86, 1.07) 
ALERT TX 143/1050 (13.6) 138/1052 (13.1) 1.02 (0.81, 1.30) 
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